新辅助化疗地点对胰腺癌手术时机与长期结局的影响
本研究基于单中心前瞻性数据库,纳入2016年1月至2020年2月接受新辅助化疗后行肿瘤切除的179例胰腺腺癌患者,按化疗地点分为同院、同系统外院及系统外院三组。
要点
- 新辅助化疗地点不影响完成治疗至手术的时间间隔。
- 可在本地中心接受新辅助化疗而不影响围术期死亡与长期生存。
核心结论
- 胰腺腺癌患者在当地中心接受新辅助化疗不阻碍手术安排。
- 虽术后再入院率可能较高,但围术期死亡与长期生存不受化疗地点不利影响。
研究设计与样本
- 单中心高容量机构前瞻性维护数据库的回顾性队列研究。
- 纳入2016年1月至2020年2月接受新辅助化疗后行肿瘤切除的胰腺腺癌患者179例。
主要发现
- 完成新辅助治疗至手术时间三组无显著差异(中位[四分位距]:34.5[14] vs 41.5[24] vs 36[22]天,P = .08)。
- 90天死亡率与总生存三组无显著差异。
临床怎么用
- 胰腺腺癌患者可在本地中心完成新辅助化疗,不延误手术安排。
- 需关注系统外院化疗患者术后再入院风险,加强围术期管理。
- 多学科诊疗可在不同地点有效开展而不影响总体结局。
局限性
- 单中心高容量机构回顾性研究,样本量有限。
- 同系统外院组仅20例,组间比较需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although high-volume centers are known to have better surgical outcomes, patients with pancreatic adenocarcinoma often receive chemotherapy at treatment centers closer to home. This study aimed to determine whether treatment site of neoadjuvant therapy relative to surgery location impacts surgical timing and long-term outcomes. METHODS: All patients with pancreatic adenocarcinoma who underwent oncologic resection at a single, high-volume institution between January 2016 and February 2020 and had neoadjuvant chemotherapy before surgery were queried from a prospectively maintained database. Patients were sorted based on location of neoadjuvant chemotherapy. RESULTS: A total of 179 patients were included in the study. Seventy-four (41.3%) patients received neoadjuvant chemotherapy at the same institution as their surgery (group A), 20 (11.2%) received chemotherapy outside of their surgical institution but within the same hospital/healthcare system (group B), and 85 (47.5%) received chemotherapy at an outside location (group C). The time from completion of neoadjuvant therapy to surgery was not significantly different between groups (A vs B vs C median [interquartile range]: 34.5 [14] vs 41.5 [24] vs 36 [22] days, P = .08). Thirty-day readmission rate was lower in group A (n (%): 1 (1.4%) vs 2 (10.0%) vs 11 (12.9%), P = .02). However, the 90-day mortality and overall survival did not differ significantly between groups. CONCLUSION: Patients may receive neoadjuvant therapy at local centers without impacting surgical scheduling. Although these patients may experience higher postoperative readmission rates, perioperative mortality and long-term survival are not adversely affected by location of chemotherapy. Multidisciplinary care can be effectively practiced in different locations without affecting overall outcomes in patients with pancreatic adenocarcinoma.
引用
- Kim RC, Allen KA, Roch AM, et al. Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcomes in patients with pancreatic adenocarcinoma. Surgery. 2022. PMID: 36253310. doi:10.1016/j.surg.2022.06.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。